The protein EZH2 is found in a great majority (74 percent) of hormone-receptor-negative tumors, mostly in triple negative. It is linked to larger tumor size—over 2 cm—and affected lymph nodes, according to research presented at the 2009 annual meeting of the American Society of Clinical Oncology.
Researchers speculate that EZH2 could ultimately be much-needed therapy for women with hormone-negative breast cancer. The study is continuing with the goal of determining EZH2's role in survival of hormone-negative cancer.
No comments:
Post a Comment